Mayne Pharma Group Limited (MAYNF) Análisis de Acciones
Solo con fines informativos. No es asesoramiento financiero. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Cotizando a $, Mayne Pharma Group Limited (MAYNF) es una empresa del sector Healthcare valorada en 0. Calificado con 43/100 (cauteloso) en potencial de crecimiento, salud financiera e impulso.
Ultimo analisis: 16 mar 2026Mayne Pharma Group Limited (MAYNF) Resumen de Asistencia Médica y Tuberías
Mayne Pharma Group Limited, based in Australia, develops, manufactures, and markets pharmaceutical products globally. With a focus on oral drug delivery and specialty areas like dermatology and women's health, the company operates through four segments, including contract services and international distribution, facing competition in the general drug manufacturing sector.
Tesis de Inversión
Mayne Pharma Group Limited presents a complex investment case. With a market capitalization of $0.15 billion and a negative P/E ratio of -2.24, the company's profitability is a concern, evidenced by a negative profit margin of -20.4%. However, a gross margin of 54.8% indicates potential in operational efficiency. Key value drivers include the Metrics Contract Services segment and international expansion. Growth catalysts involve new product launches and strategic partnerships. Potential risks include regulatory challenges, competition from generic manufacturers, and the company's ability to achieve sustained profitability. Investors should closely monitor the company's financial performance and strategic initiatives.
Basado en las finanzas de FMP y el análisis cuantitativo
Puntos clave
- Market capitalization of $0.15 billion indicates its size relative to competitors.
- Negative P/E ratio of -2.24 reflects current unprofitability.
- Profit margin of -20.4% highlights operational challenges.
- Gross margin of 54.8% suggests potential for profitability with improved cost management.
- Beta of 0.98 indicates volatility similar to the overall market.
Competidores y Pares
Fortalezas
- Diverse product portfolio across branded and generic pharmaceuticals.
- Global presence with operations in multiple regions.
- Established manufacturing capabilities.
- Contract services segment provides a stable revenue stream.
Debilidades
- Negative profit margin indicates financial challenges.
- High debt levels may constrain growth opportunities.
- Dependence on key products and markets.
- Exposure to regulatory risks and pricing pressures.
Catalizadores
- Upcoming: Potential new product launches in dermatology and women's health.
- Ongoing: Expansion of Metrics Contract Services through new partnerships.
- Ongoing: Geographic expansion into emerging markets.
- Upcoming: Regulatory approvals for key pipeline products.
- Ongoing: Cost optimization initiatives to improve profitability.
Riesgos
- Potential: Intense competition from generic and branded pharmaceutical companies.
- Potential: Regulatory changes and pricing pressures.
- Potential: Product liability claims and recalls.
- Ongoing: Negative profit margin indicates financial challenges.
- Ongoing: High debt levels may constrain growth opportunities.
Oportunidades de crecimiento
- Expansion of Metrics Contract Services: Mayne Pharma can leverage its Metrics Contract Services segment to drive growth by securing additional contracts with pharmaceutical companies seeking development, manufacturing, and analytical services. The global pharmaceutical contract manufacturing market is projected to reach $227.7 billion by 2028, presenting a significant opportunity for Mayne Pharma to increase its market share. This expansion can be achieved through targeted marketing and strategic partnerships.
- New Product Development and Launches: Mayne Pharma can invest in research and development to create and launch new branded and generic pharmaceutical products. Focusing on therapeutic areas with unmet needs, such as dermatology and women's health, can drive revenue growth. Successful product launches require regulatory approvals and effective marketing strategies. The timeline for new product development varies depending on the complexity of the drug and regulatory requirements.
- Geographic Expansion: Mayne Pharma can expand its presence in existing markets and enter new geographic regions to increase its customer base and revenue streams. Focusing on emerging markets with growing healthcare expenditures can provide significant growth opportunities. This expansion requires careful market analysis, regulatory compliance, and strategic partnerships with local distributors. The timeline for geographic expansion depends on the specific market and regulatory environment.
- Strategic Acquisitions: Mayne Pharma can pursue strategic acquisitions to expand its product portfolio, geographic reach, and manufacturing capabilities. Acquiring companies with complementary products or technologies can create synergies and drive revenue growth. Successful acquisitions require careful due diligence and integration planning. The timeline for acquisitions depends on the size and complexity of the target company.
- Partnerships and Collaborations: Mayne Pharma can form partnerships and collaborations with other pharmaceutical companies, research institutions, and healthcare providers to develop and commercialize new products and technologies. These partnerships can provide access to new markets, expertise, and resources. Successful partnerships require clear agreements and effective communication. The timeline for partnerships depends on the specific project and objectives.
Oportunidades
- Expansion into new therapeutic areas.
- Strategic acquisitions to expand product portfolio and geographic reach.
- Increased demand for generic drugs in emerging markets.
- Partnerships with other pharmaceutical companies and research institutions.
Amenazas
- Intense competition from generic and branded pharmaceutical companies.
- Regulatory changes and pricing pressures.
- Product liability claims and recalls.
- Economic downturns and currency fluctuations.
Ventajas competitivas
- Proprietary oral drug delivery systems offer a technological advantage.
- Established manufacturing capabilities provide a barrier to entry.
- Global distribution network enables access to multiple markets.
- Contract services segment provides a diversified revenue stream.
Acerca de MAYNF
Mayne Pharma Group Limited, originally Halcygen Pharmaceuticals Limited, was founded in 2005 and rebranded in 2010. Headquartered in Salisbury South, Australia, the company operates as a specialty pharmaceutical manufacturer and distributor with a global reach, including Australia, New Zealand, the United States, Canada, Europe, and Asia. The company's business is divided into four key segments: Metrics Contract Services, which provides pharmaceutical development, manufacturing, and analytical services; International, which handles distribution in various global markets; Branded Products, focusing on proprietary pharmaceuticals; and Portfolio Products, encompassing a range of established medications. Mayne Pharma specializes in oral drug delivery systems and offers a diverse portfolio of generic and branded products in therapeutic areas such as dermatology, women's health, and infectious diseases. The company aims to leverage its manufacturing capabilities and global presence to deliver pharmaceutical solutions to patients and healthcare providers.
Qué hacen
- Manufactures and sells branded pharmaceutical products.
- Manufactures and sells generic pharmaceutical products.
- Provides oral drug delivery systems.
- Offers contract pharmaceutical development services.
- Offers contract pharmaceutical manufacturing services.
- Provides contract pharmaceutical analytical services.
- Distributes specialty pharmaceutical products in dermatology.
- Distributes specialty pharmaceutical products in women's health and infectious diseases.
Modelo de Negocio
- Develops and manufactures generic and branded pharmaceuticals.
- Generates revenue through product sales in various geographic markets.
- Provides contract services to third-party pharmaceutical companies.
- Focuses on specialty therapeutic areas such as dermatology and women's health.
Contexto de la Industria
Mayne Pharma operates within the competitive drug manufacturing industry, facing pressure from both generic and branded pharmaceutical companies. The industry is characterized by stringent regulatory requirements, intense research and development, and pricing pressures. Market trends include increasing demand for generic drugs, advancements in drug delivery technologies, and a growing focus on specialty pharmaceuticals. Mayne Pharma's focus on oral drug delivery systems and contract services positions it to capitalize on these trends, but it must navigate the competitive landscape and regulatory hurdles to achieve sustainable growth.
Clientes Clave
- Patients who use their branded and generic pharmaceutical products.
- Hospitals and clinics that prescribe or administer their products.
- Pharmacies that dispense their medications.
- Third-party pharmaceutical companies utilizing their contract services.
Finanzas
Gráfico e información
Precio de la acción de Mayne Pharma Group Limited (MAYNF): Price data unavailable
Últimas noticias
-
Stocks That Hit 52-Week Lows On Tuesday
· 24 mar 2020
-
Stocks That Hit 52-Week Lows On Wednesday
· 26 feb 2020
Consenso de analistas
Calificación de Consenso
Recomendaciones agregadas de Compra/Mantener/Vender de Benzinga, Yahoo Finance y Finnhub para MAYNF.
Objetivos de Precios
Análisis del precio objetivo de Wall Street para MAYNF.
MoonshotScore
¿Qué significa esta puntuación?
El MoonshotScore califica el potencial de crecimiento de MAYNF en una escala de 0 a 100 en múltiples factores, incluyendo innovación, disrupción del mercado, salud financiera e impulso.
Liderazgo: Aaron Gray
Unknown
Information on Aaron Gray's background is limited. He currently manages 450 employees at Mayne Pharma Group Limited. Further details regarding his career history, education, and previous roles are not available in the provided data.
Historial: Due to limited information, Aaron Gray's key achievements, strategic decisions, and company milestones under his leadership cannot be assessed. Additional data is needed to evaluate his track record at Mayne Pharma Group Limited.
Información del mercado OTC de MAYNF
The OTC Other tier represents the lowest tier of the OTC market, indicating that Mayne Pharma Group Limited (MAYNF) may not meet the minimum financial or disclosure requirements for higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may not provide regular financial reporting, leading to increased risks for investors compared to companies listed on major exchanges like the NYSE or NASDAQ. The lack of stringent requirements can result in less transparency and potentially greater price volatility.
- Nivel OTC: OTC Other
- Estado de divulgación: Unknown
- Limited financial disclosure increases information asymmetry.
- Lower liquidity can lead to price volatility and difficulty in exiting positions.
- OTC Other tier companies may have a higher risk of fraud or mismanagement.
- Lack of regulatory oversight compared to exchange-listed companies.
- Potential for delisting or trading suspension due to non-compliance.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's capital structure and debt levels.
- Monitor trading volume and price volatility.
- Consult with a financial advisor before investing.
- Understand the risks associated with investing in OTC stocks.
- Company has been in operation since 2005.
- Operates in the regulated pharmaceutical industry.
- Has a global presence with operations in multiple regions.
- Employs 450 people.
Lo Que los Inversores Preguntan Sobre Mayne Pharma Group Limited (MAYNF)
¿Cuáles son los factores clave para evaluar MAYNF?
Mayne Pharma Group Limited (MAYNF) actualmente tiene una puntuación IA de 43/100, indicando puntuación baja. Fortaleza clave: Diverse product portfolio across branded and generic pharmaceuticals.. Riesgo principal a monitorear: Potential: Intense competition from generic and branded pharmaceutical companies.. Esto no es asesoramiento financiero.
¿Qué es el MoonshotScore de MAYNF?
MAYNF actualmente puntúa 43/100 (Grado D) en el MoonshotScore, lo que sugiere calificación baja. La puntuación evalúa el potencial de crecimiento, la salud financiera, el impulso del mercado y los factores de riesgo en 9 KPIs cuantitativos. Se recalcula diariamente con los últimos datos del mercado. Esta puntuación es solo informativa.
¿Con qué frecuencia se actualizan los datos de MAYNF?
Los precios de MAYNF se actualizan en tiempo real durante el horario del mercado estadounidense (9:30-16:00 ET, días laborables). Los fundamentales se actualizan después de los informes trimestrales o anuales. Las calificaciones de analistas y las perspectivas de IA se actualizan diariamente. Las noticias se agregan continuamente de fuentes financieras.
¿Qué dicen los analistas sobre MAYNF?
La cobertura de analistas para MAYNF incluye calificaciones de consenso (compra, mantener, venta), objetivos de precio a 12 meses y estimaciones de ganancias de las principales firmas de investigación. Consulte la sección de Consenso de Analistas en esta página.
¿Cuáles son los riesgos de invertir en MAYNF?
Las categorías de riesgo para MAYNF incluyen riesgo de mercado, riesgo específico de la empresa (gestión, competencia), riesgo financiero (deuda, consumo de efectivo) y riesgo macroeconómico (tasas, inflación). Un riesgo clave identificado: Potential: Intense competition from generic and branded pharmaceutical companies.. Un beta superior a 1,0 indica mayor volatilidad que el S&P 500. Revise la sección de Factores de Riesgo en esta página. Todas las inversiones conllevan riesgo de pérdida.
¿Cuál es la relación P/E de MAYNF?
La relación P/E para MAYNF compara el precio actual de la acción con sus ganancias por acción. Un P/E más alto puede indicar expectativas de crecimiento, mientras que un P/E más bajo puede sugerir valor. Consulte la pestaña de Financieros para métricas actuales.
¿Está MAYNF sobrevalorada o infravalorada?
Determinar si Mayne Pharma Group Limited (MAYNF) está sobrevalorada o infravalorada requiere examinar múltiples métricas. Compare los ratios de valoración (P/E, P/S, EV/EBITDA) con pares del sector. Esto no es asesoramiento financiero.
¿Cuál es el rendimiento por dividendo de MAYNF?
Mayne Pharma Group Limited (MAYNF) actualmente no paga un dividendo regular, o los datos de rendimiento no están disponibles. Consulte la pestaña de Financieros para información actual.
Descargo de responsabilidad: Este contenido es solo para fines informativos y no constituye asesoramiento de inversión. Siempre haga su propia investigación y consulte a un asesor financiero.
Recursos Oficiales
Datos proporcionados solo con fines informativos.
- OTC data may be less reliable than exchange-listed data.
- CEO background information is limited.